Status:
COMPLETED
Renal Impairment Study
Lead Sponsor:
AstraZeneca
Conditions:
Reflux
Renal Excretion
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to see how quickly AZD3355 is taken up in to the blood and leaves the blood in people with normal kidney function or with different degrees of reduced kidney function.
Eligibility Criteria
Inclusion
- Provision of signed informed consent
- Subjects should have either normal renal function or have a moderate renal impairment or severe renal impairment
Exclusion
- History of heart disease
- Unstable or clinically significant other disorders such as respiratory, hepatic, metabolic, psychiatric or gastrointestinal disorder
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00863161
Start Date
March 1 2009
End Date
February 1 2010
Last Update
January 24 2011
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Linköping, Sweden
2
Research Site
Luleå, Sweden
3
Research
Uppsala, Sweden